Search company, investor...


Founded Year



Incubator/Accelerator | Alive

Total Raised


About Healionics

Healionics develops and manufactures STAR Biomaterials for implanted medical devices. The precisely controlled pore structure of the STAR technology induces an integrated healing response, overcoming fibrotic reactions and infection issues to enhance medical device performance and longevity.

Headquarters Location

2121 N 35th Street Suite 200

Seattle, Washington, 98103,

United States


Missing: Healionics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Healionics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Healionics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Healionics is included in 2 Expert Collections, including Medical Devices.


Medical Devices

9,027 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Health IT

7,901 items

Healionics Patents

Healionics has filed 9 patents.

The 3 most popular patent topics include:

  • Implants (medicine)
  • Vascular surgery
  • Angiology
patents chart

Application Date

Grant Date


Related Topics




Diseases of the eye and adnexa, Disorders of choroid and retina, Ophthalmology, Blindness, Rare diseases


Application Date


Grant Date



Related Topics

Diseases of the eye and adnexa, Disorders of choroid and retina, Ophthalmology, Blindness, Rare diseases



Latest Healionics News

Healionics raises $4.7M to commercialize artificial blood vessel tech

May 17, 2021

Healionics raises $4.7M to commercialize artificial blood vessel tech May 13, 2021 at 10:58 am Share  7 Healionics’ STARgraft vascular graft acts as an artificial blood vessel for dialysis patients. (Healionics Photo) New funding: Seattle-based medical technology company Healionics raised a $4.7 million round led by Keiretsu Capital to help commercialize its artificial blood vessel called STARgraft for patients who undergo dialysis treatment. Patients with failed kidneys can undergo dialysis several times per week to filter waste from the bloodstream. In administering the treatment, physicians often use a vascular graft to maintain access to the bloodstream, but current grafts often fail due to blockages, also known as vascular occlusion. STARgraft aims to provide high resistance to occlusion. “We are targeting early next year for commercial launch of STARgraft,” Healionics CEO Mike Connolly said in a statement. “This novel synthetic blood vessel, based on our proprietary STAR biomaterial technology, has the potential to improve the lives of dialysis patients by reducing the frequency and severity of infections and the frequency of interventions required to maintain dialysis access.” The cash will be used to complete a second human study and obtain FDA clearance. Healionics also said it converted $5.2 million in outstanding notes and interest to equity. Message from the Underwriter

Healionics Frequently Asked Questions (FAQ)

  • When was Healionics founded?

    Healionics was founded in 2007.

  • Where is Healionics's headquarters?

    Healionics's headquarters is located at 2121 N 35th Street, Seattle.

  • What is Healionics's latest funding round?

    Healionics's latest funding round is Incubator/Accelerator.

  • How much did Healionics raise?

    Healionics raised a total of $28.93M.

  • Who are the investors of Healionics?

    Investors of Healionics include MedTech Innovator, Keiretsu Capital, Social Venture Partners, Paycheck Protection Program, NuFund Venture Group and 11 more.

  • Who are Healionics's competitors?

    Competitors of Healionics include Tepha, MedShape, EndoMedix, Elastagen, Viveve Medical and 12 more.

Compare Healionics to Competitors

Serica Technologies

Serica is a medical device company focused on the development of silk-based biomaterial platforms that may be used in tissue repair. The company's approach leverages natural silk in combination with advances in biomedical engineering to address needs in the repair of damaged connective tissue, caused by disease, trauma, or aging. Serica's products are being studied for use in orthopaedics and sports medicine, aesthetic and reconstructive plastic surgery, and multiple additional structural tissue repair applications.


IN2BATE is prepared to enter the emergency medicine market by offering a cricothyroidotomy device. A cricothyroidotomy is an emergency procedure that is performed on patients suffering from an obstructed airway, usually caused by a trauma accident. Thorough market research has allowed for us to create a strategic advantage over the competition by creating a solution for an uncontested market space. The company's target market includes hospitals--specifically emergency departments, ambulance service companies, ambulance supply companies, and emergency response units.

SpringMed Group

The resources necessary to transform a medical device concept into a commercially viable reality are enormous. Appropriate funding in addition to Food and Drug Administration ( FDA) experience, engineering and rapid prototyping are essential in order to have any reasonable chance for success. To this end, SpringMed Group is a medical device business accelerator that has been designed and organized around core competencies that will substantially improve the development time line and successful launch of new and medical devices.

Es Vascular

ES Vascular Ltd. developed first ever surgical stapling devices for endovascular surgery. These devices aim to transform vascular surgery by shortening procedural times, and by simplifying and potentially increasing the safety of the most common vascular interventions. The company is currently developing three product lines for open AAA, endovascular AAA and Femoro-Pop bypass procedures. Its first products are anticipated to enter the market in 2008.nCompany Snapshotn Started in 2000 in Israel by Prof. Shifrin together with group of engineers and leading vascular surgeons from the US and Europe;n Developed a ever vascular stapling technology for stapling synthetic grafts to the aortan Developed endovascular devices for EVAR and SFA procedures

Suneva Medical

Suneva Medical develops differentiated products for the general dermatology and aesthetic markets. The company markets Bellafill, a dermal filler approved by the U.S. Food and Drug Administration for the correction of nasolabial folds and moderate to severe, atrophic, and distensible facial acne scars on the cheek in patients over the age of 21 years. The company was founded in 2009 and is based in San Diego, California.

Ifc Medical

Chameleon aims to transform the surfaces of medical devices to control their interaction with the human body and deliver performance. Per the company, they do this by leveraging molecular physics.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.